Neurones (NRO.PA) Stock Price
Neurones Price
Revenue has compounded at 10.4% per year over the past 19 years to 857.20 M EUR. Earnings per share have grown at 11.5% per year over the last 19 years. Neurones's net margin stands at 6.1%, broadly stable from 6.5% several years earlier. Neurones currently offers a dividend yield of about 3.41%. The payout ratio is around 61% of earnings. The dividend has grown at 17.6% per year over the past 19 years. Analysts set a median price target of 53.04 EUR, implying 39.0% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 14% above its 52-week low.
Neurones stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Neurones over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neurones stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neurones's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Neurones Price |
|---|---|
| 7/31/2026 | 38.15 EUR |
| 7/30/2026 | 38.85 EUR |
| 7/29/2026 | 39.30 EUR |
| 7/28/2026 | 36.85 EUR |
| 7/27/2026 | 36.40 EUR |
| 7/24/2026 | 35.00 EUR |
| 7/23/2026 | 35.40 EUR |
| 7/22/2026 | 36.00 EUR |
| 7/21/2026 | 35.90 EUR |
| 7/20/2026 | 35.85 EUR |
| 7/17/2026 | 35.65 EUR |
| 7/16/2026 | 35.85 EUR |
| 7/15/2026 | 36.00 EUR |
| 7/14/2026 | 35.10 EUR |
| 7/13/2026 | 35.30 EUR |
| 7/10/2026 | 35.00 EUR |
| 7/9/2026 | 35.15 EUR |
| 7/8/2026 | 35.40 EUR |
| 7/7/2026 | 36.15 EUR |
| 7/6/2026 | 35.30 EUR |
| 7/3/2026 | 35.55 EUR |
| 7/2/2026 | 35.65 EUR |
| 7/1/2026 | 35.75 EUR |
| 6/30/2026 | 34.55 EUR |
| 6/29/2026 | 34.50 EUR |
| 6/26/2026 | 33.65 EUR |
| 6/25/2026 | 33.80 EUR |
| 6/24/2026 | 35.10 EUR |
| 6/23/2026 | 35.20 EUR |
| 6/22/2026 | 35.35 EUR |
| 6/19/2026 | 34.45 EUR |
| 6/18/2026 | 34.05 EUR |
| 6/17/2026 | 34.85 EUR |
| 6/16/2026 | 35.65 EUR |
| 6/15/2026 | 36.10 EUR |
| 6/12/2026 | 35.45 EUR |
| 6/11/2026 | 35.30 EUR |
| 6/10/2026 | 36.10 EUR |
| 6/9/2026 | 37.20 EUR |
| 6/8/2026 | 38.45 EUR |
| 6/5/2026 | 39.15 EUR |
| 6/4/2026 | 38.70 EUR |
| 6/3/2026 | 39.05 EUR |
| 6/2/2026 | 39.55 EUR |
| 6/1/2026 | 39.70 EUR |
| 5/29/2026 | 39.00 EUR |
| 5/28/2026 | 38.38 EUR |
| 5/27/2026 | 38.05 EUR |
| 5/26/2026 | 38.70 EUR |
| 5/25/2026 | 39.00 EUR |
| 5/22/2026 | 39.05 EUR |
| 5/21/2026 | 38.60 EUR |
| 5/20/2026 | 38.80 EUR |
| 5/19/2026 | 38.80 EUR |
| 5/18/2026 | 38.60 EUR |
| 5/15/2026 | 38.05 EUR |
| 5/14/2026 | 37.85 EUR |
| 5/13/2026 | 37.30 EUR |
| 5/12/2026 | 36.90 EUR |
| 5/11/2026 | 37.15 EUR |
| 5/8/2026 | 37.00 EUR |
| 5/7/2026 | 37.80 EUR |
| 5/6/2026 | 36.80 EUR |
| 5/5/2026 | 36.20 EUR |
| 5/4/2026 | 36.75 EUR |
| 4/30/2026 | 35.95 EUR |
| 4/29/2026 | 35.95 EUR |
| 4/28/2026 | 35.65 EUR |
| 4/27/2026 | 35.60 EUR |
| 4/24/2026 | 36.45 EUR |
| 4/23/2026 | 37.15 EUR |
| 4/22/2026 | 37.45 EUR |
| 4/21/2026 | 38.15 EUR |
| 4/20/2026 | 38.20 EUR |
| 4/17/2026 | 38.15 EUR |
| 4/16/2026 | 37.05 EUR |
| 4/15/2026 | 36.80 EUR |
| 4/14/2026 | 36.65 EUR |
| 4/13/2026 | 36.50 EUR |
| 4/10/2026 | 36.00 EUR |
| 4/9/2026 | 36.00 EUR |
| 4/8/2026 | 36.35 EUR |
| 4/7/2026 | 36.75 EUR |
| 4/2/2026 | 36.11 EUR |
| 3/27/2026 | 34.46 EUR |
| 3/26/2026 | 34.25 EUR |
| 3/25/2026 | 34.63 EUR |
| 3/24/2026 | 33.60 EUR |
| 3/23/2026 | 34.70 EUR |
| 3/20/2026 | 34.28 EUR |
| 3/19/2026 | 34.65 EUR |
| 3/17/2026 | 35.12 EUR |
| 3/16/2026 | 34.30 EUR |
| 3/13/2026 | 34.79 EUR |
| 3/12/2026 | 36.09 EUR |
| 3/11/2026 | 34.86 EUR |
| 3/10/2026 | 34.65 EUR |
| 3/9/2026 | 34.60 EUR |
| 3/6/2026 | 34.30 EUR |
| 3/5/2026 | 35.00 EUR |
| 2/26/2026 | 34.24 EUR |
| 2/25/2026 | 33.70 EUR |
| 2/23/2026 | 33.90 EUR |
| 2/20/2026 | 35.22 EUR |
| 2/19/2026 | 35.55 EUR |
| 2/18/2026 | 35.50 EUR |
| 2/17/2026 | 34.35 EUR |
| 2/16/2026 | 34.82 EUR |
| 2/13/2026 | 35.90 EUR |
| 2/12/2026 | 36.52 EUR |
| 2/11/2026 | 37.26 EUR |
| 2/10/2026 | 39.28 EUR |
| 2/9/2026 | 40.35 EUR |
| 2/6/2026 | 39.45 EUR |
| 2/5/2026 | 39.74 EUR |
| 2/4/2026 | 39.20 EUR |
| 2/3/2026 | 41.40 EUR |
| 2/2/2026 | 41.16 EUR |
| 1/30/2026 | 40.20 EUR |
| 1/29/2026 | 39.45 EUR |
| 1/28/2026 | 39.50 EUR |
| 1/27/2026 | 39.53 EUR |
| 1/26/2026 | 39.53 EUR |
| 1/23/2026 | 40.05 EUR |
| 1/22/2026 | 40.10 EUR |
| 1/21/2026 | 40.23 EUR |
| 1/20/2026 | 41.20 EUR |
| 1/19/2026 | 41.33 EUR |
| 1/16/2026 | 41.60 EUR |
| 1/15/2026 | 42.28 EUR |
| 1/14/2026 | 41.34 EUR |
| 1/13/2026 | 41.93 EUR |
| 1/12/2026 | 42.61 EUR |
| 1/9/2026 | 42.50 EUR |
| 1/8/2026 | 42.90 EUR |
| 1/7/2026 | 43.10 EUR |
| 1/6/2026 | 42.10 EUR |
| 1/5/2026 | 42.03 EUR |
| 1/2/2026 | 42.40 EUR |
| 12/31/2025 | 42.55 EUR |
| 12/30/2025 | 42.69 EUR |
| 12/29/2025 | 42.60 EUR |
| 12/24/2025 | 42.25 EUR |
| 12/23/2025 | 42.60 EUR |
| 12/22/2025 | 42.64 EUR |
| 12/19/2025 | 42.81 EUR |
| 12/18/2025 | 42.58 EUR |
| 12/17/2025 | 42.95 EUR |
| 12/16/2025 | 44.25 EUR |
| 12/15/2025 | 44.06 EUR |
| 12/12/2025 | 43.64 EUR |
| 12/11/2025 | 43.70 EUR |
| 12/10/2025 | 43.90 EUR |
| 12/9/2025 | 44.14 EUR |
| 12/8/2025 | 44.48 EUR |
| 12/5/2025 | 44.30 EUR |
| 12/4/2025 | 44.90 EUR |
| 12/3/2025 | 44.50 EUR |
| 12/2/2025 | 44.00 EUR |
| 12/1/2025 | 43.80 EUR |
| 11/28/2025 | 43.65 EUR |
| 11/27/2025 | 43.75 EUR |
| 11/26/2025 | 43.23 EUR |
| 11/25/2025 | 42.60 EUR |
| 11/24/2025 | 43.23 EUR |
| 11/21/2025 | 42.25 EUR |
| 11/20/2025 | 42.25 EUR |
| 11/19/2025 | 42.03 EUR |
| 11/18/2025 | 41.70 EUR |
| 11/17/2025 | 42.39 EUR |
| 11/14/2025 | 42.15 EUR |
| 11/13/2025 | 42.65 EUR |
| 11/12/2025 | 43.15 EUR |
| 11/11/2025 | 43.45 EUR |
| 11/10/2025 | 43.30 EUR |
| 11/7/2025 | 42.35 EUR |
| 11/6/2025 | 41.75 EUR |
| 11/5/2025 | 38.46 EUR |
| 11/4/2025 | 38.58 EUR |
| 11/3/2025 | 39.00 EUR |
| 10/31/2025 | 39.40 EUR |
| 10/30/2025 | 39.30 EUR |
| 10/29/2025 | 39.44 EUR |
| 10/28/2025 | 39.61 EUR |
| 10/27/2025 | 39.65 EUR |
| 10/24/2025 | 39.84 EUR |
| 10/23/2025 | 39.52 EUR |
| 10/22/2025 | 39.51 EUR |
| 10/21/2025 | 39.67 EUR |
| 10/20/2025 | 39.04 EUR |
| 10/17/2025 | 38.12 EUR |
| 10/16/2025 | 38.00 EUR |
| 10/15/2025 | 38.48 EUR |
| 10/14/2025 | 38.49 EUR |
| 10/13/2025 | 38.40 EUR |
| 10/10/2025 | 38.91 EUR |
| 10/9/2025 | 39.35 EUR |
| 10/8/2025 | 39.00 EUR |
| 10/7/2025 | 38.99 EUR |
| 10/6/2025 | 38.35 EUR |
| 10/3/2025 | 39.40 EUR |
| 10/2/2025 | 38.90 EUR |
| 10/1/2025 | 39.61 EUR |
| 9/30/2025 | 39.75 EUR |
| 9/29/2025 | 39.50 EUR |
| 9/26/2025 | 38.80 EUR |
| 9/25/2025 | 39.15 EUR |
| 9/24/2025 | 40.10 EUR |
| 9/23/2025 | 40.01 EUR |
| 9/22/2025 | 39.74 EUR |
| 9/19/2025 | 39.91 EUR |
| 9/18/2025 | 40.44 EUR |
| 9/17/2025 | 39.97 EUR |
| 9/16/2025 | 39.82 EUR |
| 9/15/2025 | 40.10 EUR |
| 9/12/2025 | 39.55 EUR |
| 9/11/2025 | 40.80 EUR |
| 9/10/2025 | 41.16 EUR |
| 9/9/2025 | 39.99 EUR |
| 9/8/2025 | 39.58 EUR |
| 9/5/2025 | 39.71 EUR |
| 9/4/2025 | 39.82 EUR |
| 9/3/2025 | 39.67 EUR |
| 9/2/2025 | 39.83 EUR |
| 9/1/2025 | 40.50 EUR |
| 8/29/2025 | 40.51 EUR |
| 8/28/2025 | 41.01 EUR |
| 8/27/2025 | 41.40 EUR |
| 8/26/2025 | 42.15 EUR |
| 8/25/2025 | 43.24 EUR |
| 8/22/2025 | 42.27 EUR |
| 8/21/2025 | 42.13 EUR |
| 8/20/2025 | 41.98 EUR |
| 8/19/2025 | 42.50 EUR |
| 8/18/2025 | 41.85 EUR |
| 8/15/2025 | 41.00 EUR |
| 8/14/2025 | 41.29 EUR |
| 8/13/2025 | 42.00 EUR |
| 8/12/2025 | 42.50 EUR |
| 8/11/2025 | 42.50 EUR |
| 8/8/2025 | 41.91 EUR |
| 8/7/2025 | 42.09 EUR |
| 8/6/2025 | 43.37 EUR |
| 8/5/2025 | 43.28 EUR |
| 8/4/2025 | 42.71 EUR |
Neurones Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Neurones Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| DIVIDENDDIV.EUR |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 343.00 | 355.00 | 399.00 | 446.00 | 485.00 | 490.00 | 510.00 | 524.00 | 579.00 | 665.00 | 741.00 | 810.00 | 857.00 | 904.00 | 949.00 | 992.00 |
| 8.89 | 3.50 | 12.39 | 11.78 | 8.74 | 1.03 | 4.08 | 2.75 | 10.50 | 14.85 | 11.43 | 9.31 | 5.80 | 5.48 | 4.98 | 4.53 |
| 34.40 | 33.52 | 35.59 | 37.00 | 38.35 | 40.20 | 42.35 | 12.98 | 11.92 | 12.18 | 46.69 | 47.90 | 10.50 | 10.50 | 10.50 | 10.50 |
| 118.00 | 119.00 | 142.00 | 165.00 | 186.00 | 197.00 | 216.00 | 68.00 | 69.00 | 81.00 | 346.00 | 388.00 | 90.00 | 94.94 | 99.66 | 104.18 |
| 32.00 | 35.00 | 37.00 | 42.00 | 44.00 | 45.00 | 53.00 | 53.00 | 61.00 | 72.00 | 75.00 | 77.00 | 72.00 | 91.00 | 96.00 | 100.00 |
| 9.33 | 9.86 | 9.27 | 9.42 | 9.07 | 9.18 | 10.39 | 10.11 | 10.54 | 10.83 | 10.12 | 9.51 | 8.40 | 10.07 | 10.12 | 10.08 |
| 18.00 | 20.00 | 21.00 | 25.00 | 27.00 | 25.00 | 30.00 | 30.00 | 37.00 | 44.00 | 49.00 | 52.00 | 52.00 | 56.00 | 62.00 | 68.00 |
| 28.57 | 11.11 | 5.00 | 19.05 | 8.00 | -7.41 | 20.00 | – | 23.33 | 18.92 | 11.36 | 6.12 | – | 7.69 | 10.71 | 9.68 |
| 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.20 | – | 1.00 | 1.10 | 1.20 | 1.30 | 1.56 | 1.87 | 2.25 |
| – | – | – | – | – | – | – | 233.33 | – | – | 10.00 | 9.09 | 8.33 | 20.00 | 19.87 | 20.32 |
| 23.84 | 24.23 | 24.25 | 24.24 | 24.29 | 24.30 | 24.29 | 24.27 | 24.25 | 24.29 | 24.31 | 24.35 | 24.33 | 24.33 | 24.33 | 24.33 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Neurones generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neurones retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neurones's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Neurones has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neurones's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Neurones stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Neurones Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Neurones business model & stock analysis
Neurones SWOT Analysis
Strengths
Neurones SA has several strengths that contribute to its success in the market. These include:
- Strong market presence and brand reputation
- Diverse portfolio of innovative products and services
- Skilled and experienced workforce
- Solid financial performance and stability
Weaknesses
Despite its strengths, Neurones SA also faces certain weaknesses that it should address for further growth:
- Limited geographical presence in certain markets
- Reliance on a few key clients for a significant portion of revenue
- Potential vulnerability to economic downturns
- Higher operational costs compared to some competitors
Opportunities
Neurones SA can capitalize on several opportunities to expand and enhance its business:
- Growing demand for digital transformation services
- Emerging markets with untapped potential
- Strategic partnerships and collaborations
- Increasing trend towards outsourcing IT services
Threats
There are various external factors that may pose challenges to Neurones SA:
- Intense competition from established and new players
- Rapid technological advancements that require continuous adaptation
- Regulatory changes impacting the industry
- Economic and market uncertainties affecting client spending
Neurones Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Neurones historical P/E ratio, EBIT multiple, and P/S ratio
Neurones annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Neurones shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Neurones Dividend History
21 years of dividend payments · 3 consecutive increases
Neurones dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Neurones dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Neurones forecasts and price targets in August 2026
Analyst Price Targets 2026Neurones shareholder structure
| % | Name |
|---|---|
1.41851% | |
0.82114% | |
0.73906% | |
0.54516% | |
0.47509% | |
0.47072% |
Neurones Beneficial Ownership Filings (SEC 13D/G)
Neurones Executives and Management Board
8 members · avg. age 72 · 25 % women
Mr. Luc De Chammard (69)
Chairman of the Board, Chief Executive Officer · since 1984
260,000.00 EUR
Management
Mr. Bertrand Ducurtil (65)
Executive Vice President · since 1999
Board of Directors
Mr. Herve Pichard (70)
Director
Mr. Jean-Louis Pacquement (70)
Independent Director
Ms. Daphne De Chammard (76)
Director, Representative of Host Développement SAS
Ms. Marie-Francoise Jaubert (83)
Independent Director
Mr. Paul-Cesar Bonnel
Director - Finance & Administration, IR Contact
Mr. Herve Robert-Peillard
Director, Representative of the Employees
Neurones Supply Chain
Neurones Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.15 | 0.63 | 0.93 | ||
| 2 | 0.52 | 0.73 | 0.91 | ||
| 3 | -0.25 | 0.64 | 0.90 | ||
| 4 | 0.38 | 0.24 | 0.90 | ||
| 5 | 0.07 | 0.36 | 0.88 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | EASYVISTA SA | -0.19 | — | — | |
| 2 | -0.28 | 0.09 | — | ||
| 3 | 0.20 | -0.54 | -0.51 | ||
| 4 | 0.20 | -0.59 | -0.38 | ||
| 5 | 0.31 | -0.02 | -0.10 |
Frequently asked questions about Neurones
The business model of Neurones SA revolves around providing IT services and solutions to various industries. Neurones SA offers a wide range of services including consulting, system integration, infrastructure management, and software solutions. The company focuses on developing innovative and cost-effective IT solutions to help their clients optimize their business processes and improve overall performance. Neurones SA aims to meet the evolving technology needs of its clients by staying updated with the latest advancements in the IT sector. With its expertise and experience, Neurones SA strives to deliver high-quality IT services and solutions tailored to the specific requirements of each client.
Neurones SA is primarily active in the IT and management consulting industries.
The main competitors of Neurones SA in the market include Atos, Capgemini, and Sopra Steria.
Neurones SA is a renowned French IT services company established in 1984. With over 30 years of experience, Neurones has become a leading player in the industry, delivering innovative digital solutions to a wide range of clients. Initially focused on mainframe computer services, the company quickly expanded its expertise to cover emerging technologies, such as internet and e-business solutions, as well as information systems security. Neurones SA delivers high-quality services encompassing consulting, systems integration, infrastructure management, and outsourcing. Through strategic partnerships, continuous innovation, and a talented workforce, Neurones SA has solidified its position as a trusted provider of IT solutions globally.
Some significant milestones achieved by Neurones SA include its creation in 1985, listing on the Paris Stock Exchange in 1999, and being recognized as a key player in digital transformation services. The company has consistently expanded its expertise in areas such as digital services, cybersecurity, and artificial intelligence. Neurones SA has also formed strategic partnerships and made numerous acquisitions to strengthen its position in the market. With a strong track record of delivering innovative solutions to its clients, the company continues to thrive and contribute to the advancement of technology-driven businesses.
Neurones SA is primarily present in France, where the company is headquartered. As a leading French IT services and consulting firm, Neurones SA has established a strong presence in various regions across the country. With a focus on delivering innovative solutions and expertise in digital transformation, Neurones SA has expanded its operations in other countries as well. While primarily present in France, the company also has a presence in other European countries, including Belgium, Luxembourg, and Switzerland. Neurones SA's commitment to providing cutting-edge technology solutions has allowed them to become a trusted partner for businesses not only in France but also in select international markets.
Neurones SA represents a strong set of values and a clear corporate philosophy. The company values include excellence, innovation, and commitment. Neurones SA strives for excellence in all areas of its business, ensuring high-quality services and solutions for its clients. The company fosters innovation, constantly seeking new ways to improve and adapt to the rapidly changing business landscape. Neurones SA also emphasizes commitment, both towards its clients and its employees, fostering strong and long-lasting relationships. Overall, Neurones SA prides itself on being a trustworthy and reliable partner, driven by its values and corporate philosophy.
Analysts currently set an average price target of 53.04 EUR for the Neurones stock (median: 53.04 EUR), implying +39.0 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Neurones stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neurones to generate revenue of 904.35 M EUR and earnings per share of 2.33 EUR.
The Neurones share (NRO.PA) is listed on 6 stock exchanges, including: Frankfurt (NE9.F), München (NE9.MU), London (0GX2.L), London (0GX2.L), Paris (NRO.PA).
The company Neurones SA is a large company that offers various services in the field of IT and digital transformation. The company was founded in 1989 and is headquartered in France. Neurones SA's services are used by companies of all sizes and industries. The business model of Neurones SA is based on three pillars: Professional Services, Software, and Transformation. Professional Services include consulting, planning, and implementation of IT projects. The company works in partnership with customers to develop and implement customized solutions for their business needs. Neurones SA also offers outsourcing services to facilitate the operation of IT systems for customers. The software division of Neurones SA includes products and solutions developed by the company. The main products include cybersecurity solutions to help customers protect their systems and data from threats. The company also offers software tools that can improve the efficiency of IT systems and reduce costs. These solutions are used by companies of all sizes and industries to optimize their business processes. The third pillar of Neurones SA's business model is transformation. The company believes that the digitalization of society and the economy requires transformation. This involves adapting business models and introducing new technologies to remain competitive. Neurones SA provides consulting and implementation services to support companies in their digital transformation. The company works with its customers to rethink business processes, introduce new technologies such as artificial intelligence and blockchain, and support employees in adapting to new work methods and tools. Neurones SA offers a wide range of services that are used by medium-sized companies to large multinational corporations in various industries. The company's broad portfolio allows it to meet the individual needs of each customer with its services. The company operates in Europe and North Africa and has a network of over 8,000 experts in various fields. Neurones SA's employees are highly qualified IT specialists, consultants, and project managers who work closely with customers to develop customized business solutions. In summary, Neurones SA's business model is based on three pillars: Professional Services, Software, and Transformation. With its wide range of services and products, the company has achieved a strong position in the market for IT consulting and digital transformation. The company works closely with its customers to develop customized solutions for their business needs. The company operates in Europe and North Africa and offers its customers a wide range of services ranging from consulting and planning to implementation and operation.
The expected revenue of Neurones is 904.35 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neurones is 56.68 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neurones is currently 16.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neurones stock.
The price-to-sales ratio (P/S) of Neurones is currently 1.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neurones stock.
The Eulerpool Quality Score for Neurones is 7/10.
The ISIN of Neurones is FR0004050250. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Neurones is 938282. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Neurones is NRO.PA. The ticker symbol is used to trade Neurones shares on the stock exchange.
Over the past 12 months, Neurones paid a dividend of 1.30 EUR . This corresponds to a dividend yield of about 3.41 %. For the coming 12 months, Neurones is expected to pay a dividend of 1.87 EUR.
The current dividend yield of Neurones is 3.41 %.
Neurones pays a dividend, distributed in the months of , , , .
Neurones paid dividends every year for the past 21 years.
For the upcoming 12 months, dividends amounting to 1.87 EUR are expected. This corresponds to a dividend yield of 4.91 %.
Neurones is assigned to the 'Information technology' sector.
To receive the latest dividend of Neurones from amounting to 1.3 EUR, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Neurones distributed 1.2 EUR as dividends.
The dividends of Neurones are distributed in EUR.
Neurones stock
Neurones Peer Group
Neurones Ticker
Neurones FIGI
All fundamentals and in-depth analysis of Neurones
Our stock analysis for Neurones stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neurones. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.